Sign Out
In clinical studies doses up to 40 mg/kg body weight were used. IARs are more likely to occur with higher dose or infusion rates than recommended (see Precautions).
Symptoms and signs: IARs have been reported, which included: cyanosis, tachycardia, palpitations; hypoxia, dyspnoea, cough; dizziness, headache, dysgeusia; hypertension, flushing; tongue oedema, vomiting, diarrhoea, nausea; chest pain, chest discomfort, throat tightness, pyrexia, chills, feeling cold, infusion site erythema; myalgia; erythema.
Management: In the event of overdose, the infusion rate should be reduced, or the infusion temporarily interrupted. There is no known specific antidote for alglucosidase alfa overdose. The patient should be monitored for any signs or symptoms of adverse reactions and administered appropriate symptomatic treatment immediately.
